Management and impact of atrial fibrillation in the COVID 19 era; concomitancy of two procoagulant phenomena

Back

ESC Premium Access

Management and impact of atrial fibrillation in the COVID 19 era; concomitancy of two procoagulant phenomena

Session: COVID-19 and cardiovascular pharmacotherapy

Topic: Anticoagulants

Speaker: Mr A. Arteagoitia Bolumburu (Madrid, ES)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

Add to my library

About the speaker

Mr Ander Arteagoitia Bolumburu

Ramon and Cajal University Hospital, Madrid (Spain)

0 follower

4 more presentations in this session

Effect of prophylactic and therapeutic low molecular weight heparins on mortality in 15,704 COVID-19 patients. A systematic review and a meta-analysis.

Speaker: Doctor A. Pani (Milan, IT)

Antiplatelet therapy and outcome in patients with COVID-19. Results from a multi-center international prospective registry (HOPE-COVID19).

Speaker: Doctor F. Santoro (Foggia, IT)

Early experience utilizing bivalirudin as anticoagulation in extracorporeal membrane oxygen in coronavirus disease 2019

Speaker: Doctor C. Jones (West Palm Beach, US)

Effect of statins on mortality in patients with COVID-19: an updated meta-analysis of 147824 patients

Speaker: Doctor C. Diaz-Arocutipa (Lima, PE)

Access the full session

COVID-19 and cardiovascular pharmacotherapy

Speakers: Mr A. Arteagoitia Bolumburu, Doctor A. Pani, Doctor F. Santoro, Doctor C. Jones, Doctor C. Diaz-Arocutipa

Access

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources